Roflumilast Ocular Delivery Lateral Migration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic delivery methods face challenges in effectively and safely delivering roflumilast to the ocular surface and anterior tissues of the eye while minimizing exposure to posterior tissues, due to issues with sterility, tolerability, and the need for elevated drug levels in inflammatory ocular diseases.
Innovation Solution
The method involves administering a pharmaceutical composition comprising roflumilast topically to the cornea, which preferentially migrates laterally through ocular surface tissues, resulting in elevated levels in the cornea, conjunctiva, iris-ciliary body, sclera, and aqueous humor relative to posterior tissues, achieving a depot effect for sustained therapeutic levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ophthalmic delivery methods are used to deliver roflumilast to the ocular surface and anterior tissues, then therapeutic levels can be achieved in target tissues, but exposure to posterior tissues cannot be sufficiently minimized
Solution Approach 1:
The invention utilizes the unique property of roflumilast to achieve localized drug distribution in ocular tissues. The compound preferentially accumulates in the cornea and anterior segments while maintaining low levels in posterior tissues, creating a localized therapeutic effect that spares posterior structures from unnecessary exposure.
2Reliability
If conventional ophthalmic formulations are used, then sterility and tolerability can be maintained, but effective drug delivery to ocular surface and anterior tissues is compromised
Solution Approach 1:
The invention changes the key parameter of drug distribution pattern by utilizing roflumilast's unique tissue selectivity. This parameter change enables conventional ophthalmic formulations to achieve both safety (sterility and tolerability) and efficacy (effective drug delivery to ocular surface and anterior tissues) simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for effective and sustained delivery of roflumilast to the ocular surface and anterior tissues, reducing exposure to posterior tissues and providing therapeutic levels for extended periods, addressing the limitations of existing delivery methods.
Implementation Method 1
roflumilast has been found preferentially to migrate laterally through the ocular surface and anterior tissues, rather than transversely through the cornea
Implementation Method 2
achieving a depot effect for sustained therapeutic levels
Data Source
AI summary
Methods for the ophthalmic delivery of roflumilast. The inventors have made the surprising discovery that the administration of pharmaceutical compositions comprising roflumilast to the cornea preferentially delivers the drug laterally through the ocular surface and anterior tissues of the eye. In contrast to the delivery of roflumilast to the skin, which primarily travels transversely through the various tissues of the skin, or many other topical ocular pharmaceutical compositions which travel through the cornea to the aqueous humor, the delivery of drug to the eye to the cornea travels laterally to the ocular surface and anterior tissues of the eye. Such methods can result in elevated levels of the drug in the cornea and other ocular surface and anterior tissues of the eye (e.g., iris-ciliary body, sclera, conjunctiva, and aqueous humor) relative to the interior or posterior tissues of the eye.